WO2011070010A1 - Prébiotique - Google Patents

Prébiotique Download PDF

Info

Publication number
WO2011070010A1
WO2011070010A1 PCT/EP2010/069066 EP2010069066W WO2011070010A1 WO 2011070010 A1 WO2011070010 A1 WO 2011070010A1 EP 2010069066 W EP2010069066 W EP 2010069066W WO 2011070010 A1 WO2011070010 A1 WO 2011070010A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucopyranoside
glyceryl
probiotic
composition
prebiotic
Prior art date
Application number
PCT/EP2010/069066
Other languages
English (en)
Inventor
Alexandra Schwarz
Bernd Nidetzky
Original Assignee
Technische Universität Graz
Forschungsholding Tu Graz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität Graz, Forschungsholding Tu Graz Gmbh filed Critical Technische Universität Graz
Priority to EP10787459.6A priority Critical patent/EP2509450B1/fr
Publication of WO2011070010A1 publication Critical patent/WO2011070010A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the use of 2-O-glyceryl- - D-glucopyranoside as prebiotic.
  • Prebiotics are non digestible food ingredients which stimu ⁇ late the growth and activity of beneficial microorganisms in the intestinal tract, mainly bifidobacteria and lactobacilli .
  • the function of prebiotic substances is - in contrast to probiotic bacteria - not affected by the cooking process.
  • Prebiotics mainly consist of oligosaccharides, sugar molecules of three to six chains and soluble fiber.
  • Probiotic bacteria are normally not found in the human in ⁇ testinal tract, because these bacteria do not colonize well and are eliminated rather quickly. Prebiotic food ingredients en ⁇ courage probiotic organisms to survive and thrive in the human gut .
  • Prebiotics and probiotics together show anticarcinogenic and antimicrobial activity, may lower triglyceride levels, sta ⁇ bilize blood glucose levels, boost the immune system, help to improve mineral absorption and balance, rid the gut of harmful microorganisms and help to prevent constipation and diarrhea.
  • Prebiotic carbohydrates are regularly found in fruit and vegetables such as bananas, berries, asparagus, garlic, wheat, oatmeal, barley (and other whole grains) , flaxseed, tomatoes, Jerusalem artichoke, onions and chicory, spinach, chard, kale, and legumes like lentils, kidney beans, chickpeas, navy beans, white beans and black beans.
  • Oligosaccharides which exhibit prebiotics characteristics are, for instance, fiber gums, fructo-oligosaccharides (FOS) , inulins, isomalto-oligosaccharides , lactilol, lactosucrose, lac ⁇ tulose, oligofructose, pyrodextrins , soy oligosaccharides, transgalacto-oligosaccharides (TOS) , and xylo-oligosaccharides .
  • FOS fructo-oligosaccharides
  • inulins isomalto-oligosaccharides
  • lactilol lactosucrose
  • lac ⁇ tulose lac ⁇ tulose
  • oligofructose pyrodextrins
  • soy oligosaccharides transgalacto-oligosaccharides (TOS)
  • TOS transgalacto-oligosaccharides
  • prebiotics have several disadvan ⁇ tages. Some of the prebiotics known have no selective effect on specific intestinal bacteria. This means that theses prebiotics support the growth of all organisms in the intestinal tract, in ⁇ differently from their benefit to the human health. Other pre ⁇ biotics cause flatulences, abdominal pain, eructation, bloating stomach, diarrhoea (due to osmogenic retention of fluid in the intestine) or even allergic reactions. Lactulose has been found to be unpalatable and may cause nausea, vomiting, abdominal cramps and diarrhoea.
  • the present invention relates to the use of 2-O-glyceryl- - D-glucopyranoside as prebiotic.
  • 2-O-glyceryl- -D-glucopyranoside is a naturally occur ⁇ ring molecule (a glycoside; a carbohydrate derivative) which serves the function of an osmoprotective substance and stabi ⁇ lizer in various microorganisms.
  • GG 2-O-glyceryl- -D-glucopyranoside
  • Several publications have shown that isolated 2-O-glyceryl- -D-glucopyranoside has a range of outstanding properties which are of substantial interest for technological application.
  • Uses of 2-O-glyceryl- -D- glucopyranoside and derivatives thereof include but are not lim ⁇ ited to the fields of medicine (cancer therapy) , cosmetics
  • 2-O-glyceryl- -D-glucopyranoside is a very efficient stabilizer of biomolecules (proteins, lip ⁇ ids) .
  • 2-O-glyceryl- -D- glucopyranoside specifically stimulates the growth of probiotic microorganisms like Lactobacillus acidophilus and bifidobacte ⁇ ria.
  • probiotic microorganisms like Lactobacillus acidophilus and bifidobacte ⁇ ria.
  • the growth of other intestinal microorganisms like Lactobacillus acidophilus and bifidobacte ⁇ ria.
  • 2-O-glyceryl- -D-glucopyranoside is not or not substantially influ ⁇ enced when 2-O-glyceryl- -D-glucopyranoside is administered to an individual or when said microorganisms are cultivated in a medium comprising 2-O-glyceryl- -D-glucopyranoside .
  • 2-O-glyceryl- -D-glucopyranoside can be produced by chemical as well as by enzymatic methods. Chemical methods may involve various start compounds like maltitol, isomaltose, trehalulose etc. (see e.g. Takenaka F. et al . Biosci. Biotechnol. Biochem.
  • Enzymes which catalyze the synthesis of 2-0- glyceryl- -D-glucopyranoside may involve -glucosidase (Takenaka F. and Uchiyama H. Biosci. Biotechnol. Biochem. (2000) 64:1821- 1826), cyclodextrin glucanotransferase (Nakano H. et al . J.
  • 2-O-glyceryl- -D-glucopyranoside is comprised in a prebiotic composition comprising at least one probiotic microroganism, in particular probiotic bacteria, and/or at least one compound se ⁇ lected from the group consisting of enzymes, vitamins, amino ac ⁇ ids, mineral salts, preservatives, stabilizers, sweeteners, fla ⁇ vourings, carriers, lubricants, dispersers, thickeners, humec- tants and gelling agents.
  • composition may also comprise one or more probiotic mi ⁇ croorganisms unable to directly ferment 2-O-glyceryl- -D- glucopyranoside as such, having complementary features, namely different intrinsic properties.
  • the at least one probiotic microorganism is preferably se ⁇ lected from the group of Lactobacilli, Bifidobacteria, Strepto ⁇ cocci, Lactococci and Saccharomyces .
  • probiotic microorganisms are espe ⁇ cially suited to be combined with 2-O-glyceryl- -D- glucopyranoside .
  • probiotics are able to grow significantly better in the presence of 2-O-glyceryl- -D- glucopyranoside compared to other non-probiotic microorganisms present in the intestinal tract.
  • Particularly preferred probiotic microorganisms are lactic acid bacteria, bifidobacteria and bacilli. These microorganisms are preferably selected from the group consisting of Bacillus coagulans, Bifidobacterium animalis subsp. lactis (BB-12), Bifi ⁇ dobacterium breve (Yakult) , Bifidobacterium infantis (35624), Bifidobacterium animalis subsp.
  • lactis HN019 (DR10)
  • Bifido ⁇ bacterium longum BB536
  • Lactobacillus acidophilus DDS-1 Lac ⁇ tobacillus acidophilus LA-5
  • Lactobacillus acidophilus NCFM Lactobacillus casei DN114-001
  • Lactobacillus casei CRL431 Lac ⁇ tobacillus casei F19
  • Lactobacillus casei Shirota Lactobacillus paracasei (Stll (or NCC2461)
  • Lactococcus lactis Lactobacillus plantarum
  • Lactobacillus reuteri (ATTC 55730), Lactobacillus rham- nosus ATCC 53013, Lactobacillus rhamnosus LB21, Lactobacillus pentosus, Lactobacillus grasseri, Saccharomyces cerevisiae (bou- lardii) and combinations thereof.
  • Preferred combinations com ⁇ prise Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC- 14; Lactobacillus acidophilus NCFM and Bifidobacterium bifidum BB-12; Lactobacillus acidophilus CL1285 and Lactobacillus casei; Lactobacillus helveticus R0052 and Lactobacillus rhamnosus
  • Streptococcus thermophilus Lactobacillus acidophilus and Bifi ⁇ dobacterium longum; Lactobacillus acidophilus , Bifidobacterium bifidum and Bifidobacterium longum; Bifidobacterium bifidum, Lactobacillus acidophilus , Lactobacillus rhamnosus , Bifidobacte ⁇ rium breve, Bifidobacterium longum, Lactobacillus casei, Lacto ⁇ bacillus plantarum, Lactococcus lactis, Lactobacillus bulgaricus and Lactobacillus salivarius .
  • 2-O-glyceryl- -D-glucopyranoside is provided in said composition in an amount of 0,01 to 20% (w/w) , preferably 0,05 to 10% (w/w) , more preferably 0,1 to 5% (w/w) .
  • the prebiotic compo ⁇ sition of the present invention may also comprise up to 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% 2-O-glyceryl- -D- glucopyranoside .
  • the probiotic microorganism which may be present in the pre ⁇ biotic composition of the present invention may be comprised in said composition m an amount of 10 -10 cfu (colony forming unit)/g of the composition, preferably 10 2 -10 8 cfu/g, more pref ⁇ erably 10 2 -10 6 cfu/g.
  • Another aspect of the present invention relates to a symbi ⁇ otic composition
  • a symbi ⁇ otic composition comprising 2-O-glyceryl- -D-glucopyranoside as prebiotic and at least one probiotic microorganism.
  • prebiotic 2-O-glyceryl- - D-glucopyranoside together with at least one probiotic microor ⁇ ganism in one single composition.
  • Said symbiotic composition may have different forms depending on the route of administration.
  • the composition according to the present invention may be introduced into a delivery tube, such as an enteral feeding tube, preferably by first wetting the particulate beneficial substance and then placing it in the tube's conduit, where it is directly conveyed to the gastrointestinal tract, preferably downstream of the stomach and most preferably to the jejunum. This may be done by placing the composition of the present in ⁇ vention into a syringe and adding water. The dispersion obtained can then be placed directly into the conduit.
  • a delivery tube such as an enteral feeding tube
  • symbiotic composition refers to a composition or product comprising probiotic microorganisms as well as prebiotics.
  • the prebiotic 2-O-glyceryl- -D-glucopyranoside or the com ⁇ position comprising said prebiotic is provided in the form of a tablet or capsule.
  • a capsule or tablet suitable for at least partially protecting the probiotic as it passes through the stomach, thus allowing a greater amount of probiotic to enter the large intestine than would enter without use of the capsule or tablet, may be used.
  • Such a tablet may have a generally ho ⁇ mogenous composition or include individual layers containing the various constituents of the tablet (such as the probiotic and prebiotic) .
  • Tablets according to the invention can be produced in any suitable manner, and two particular methods are described here ⁇ in. First, the powder mixtures of carriers and auxiliaries
  • active ingredients e.g., release agents
  • active ingredients probiotics, vita ⁇ mins, prebiotics, etc.
  • the probiotic should not be exposed to any constituent that would destabiliz ⁇ ing or destroy it.
  • Each ingredient should be well dried and preferably have a water content of 0.1% or less. The powdered constituents are then tabletted to form a tablet.
  • individual layers of, for example, probiotic and prebiotic can be formed separately.
  • the layers formed in this way are then pressed to create the finished multilayer tab ⁇ let.
  • This pressing method has the advantage that the layers which have a different compressibility on account of their dif ⁇ ferent composition can be exposed to individual pressures, which can be advantageous both with respect to the shelf life of the multilayer tablet as a whole and with respect to the stability of active ingredients in the individual layers.
  • the boundary layer between two layers in juxtaposition has a smaller active surface due to the preforming, whereby the possibility of the reaction or destabilization of sensitive active ingredients, including the probiotic, is reduced.
  • 2-O-glyceryl- -D-glucopyranoside or a composition comprising 2-O-glyceryl- -D-glucopyranoside can also be provided in cap ⁇ sules.
  • the capsules according to the present invention are pref ⁇ erably gastric juice-resistant.
  • 2-O-glyceryl- -D-glucopyranoside and the probiotic microorganisms, for example, provided in said capsules are preferably freeze-dried .
  • the at least one probiotic microorganism is selected from the group of Lactobacilli, Bifidobacteria, Streptococci, Lactococci and Saccharomyces .
  • 2-O-glyceryl- -D-glucopyranoside is provided in said composition in an amount of 0,01 to 20% (w/w) , preferably 0,05 to 10% (w/w), more preferably 0,1 to 5% (w/w).
  • the prebiotic composition of the present invention may also comprise up to 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% 2-0- glyceryl- -D—glucopyranoside .
  • the probiotic microorganism which may be present in the pre ⁇ biotic composition of the present invention may be comprised in said composition m an amount of 10 -10 cfu (colony forming unit)/g of the composition, preferably 10 2 -10 8 cfu/g, more pref ⁇ erably 10 2 -10 6 cfu/g.
  • kits comprising a first unit comprising 2-O-glyceryl- -D- glucopyranoside and at least one further unit comprising at least one probiotic microorganism.
  • Unit refers to a container comprising the said compounds and microorganisms.
  • kit can be ingested together in order to allow that the prebiotic according to the present invention exhibits its beneficial effects on the probiotic organisms in ⁇ gested before, after or at the same time as the prebiotic.
  • the at least one probi ⁇ otic microorganism is selected from the group of Lactobacilli, Bifidobacteria, Streptococci, Lactococci and Saccharomyces .
  • 2-O-glyceryl- -D-glucopyranoside is provided in said composition in an amount of 0,01 to 20% (w/w) , preferably 0,05 to 10% (w/w) , more preferably 0,1 to 5% (w/w) .
  • the prebiotic compo ⁇ sition of the present invention may also comprise up to 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% 2-O-glyceryl- -D- glucopyranoside .
  • the probiotic microorganism which may be present in the pre ⁇ biotic composition of the present invention may be comprised in said composition m an amount of 10 -10 cfu (colony forming unit)/g of the composition, preferably 10 2 -10 8 cfu/g, more pref ⁇ erably 10 2 -10 6 cfu/g.
  • Another aspect of the present invention relates to a method for producing a probiotic or symbiotic composition
  • a method for producing a probiotic or symbiotic composition comprising the steps of cultivating at least one probiotic microorganism in a nutrient medium comprising 2-O-glyceryl- -D-glucopyranoside .
  • a nutrient medium comprising 2-O-glyceryl- -D- glucopyranoside can be used to cultivate probiotic microorgan ⁇ isms.
  • 2-O-glyceryl- -D-glucopyranoside can be added to any nu ⁇ trient medium which is suited to cultivate probiotic microorgan ⁇ isms.
  • the amount of 2-O-glyceryl- -D-glucopyranoside in said nu ⁇ trient medium varies from 0,01% to 5%, preferably from 0,01% to 4%, more preferably from 0,01% to 3%, even more preferably from 0,01% to 2% (w/w) .
  • When preparing the nutrient medium 2-0- glyceryl- -D-glucopyranoside is preferably added to the steril ⁇ ized nutrient medium after being solved in water and sterile filtered .
  • the at least one probiotic microorganism is selected from the group of Lactobacilli, Bifidobacteria, Streptococci, Lactococci and Saccharomyces.
  • Yet another aspect of the present invention relates to a symbiotic composition
  • a symbiotic composition comprising at least one probiotic microorganism and 2-O-glyceryl- -D-glucopyranoside obtainable from a method according to the present invention.
  • Fig. 1 shows the growth response patterns (in relation to the optical density values after 48h incubation) of different strains in media containing no carbohydrate (lined bar) , 2%
  • FIG. 2 shows the growth kinetics of Lactobacillus aci ⁇ dophilus in MRS medium in the absence (T) and presence of 2%
  • Test strains were obtained from different European culture suppliers and strain collections (Table 1) .
  • TRY medium was prepared with the following ingredients (g/L) : tryptone (10.0), peptone from soy (5.0), yeast extract (2.5), cysteine hydrochloride (0.5), K2HPO4 (2.0), magnesium chloride (0.5), zinc sulphate (0.25), calcium chloride (0.15), FeCl3 (0.01) and Tween 80 (1 mL/L) , pH 6.5.
  • En- terococci and Lactobacilli were cultured in MRS broth which was composed as follows (g/L): tryptone (10.0), meat extract (10.0), yeast extract (5.0), K2HPO4 (2.0), sodium acetate (5.0), ammonium citrate (2.0), magnesium sulphate (0.2), manganese sulphate
  • Bacteroides were cultured in reinforced clostridial medium (Oxoid CM151), pH 6.8, containing the following ingredi ⁇ ents (g/L): yeast extract (3.0), Lab-Lemco beef extract (10.0), peptone from meat (10.0), cysteine hydrochloride (0.5), sodium chloride (5.0) and sodium acetate (3.0).
  • Carbohydrate utilization was monitored using the turbidiome- ter Bioscreen C system equipped with BioLink software package (Labsystems, Finnland) which facilitates continuous optical den- sity measurements (600 nm) at the microtiter plate level. All runs were performed at 37 °C for 2 days and the turbidity of the growth medium was measured at 30 min intervals.
  • Prebiotic effects are usually determined by in vitro studies using mono- or mixed cultures followed by in vivo studies in an ⁇ imals and/or humans.
  • microorganisms are able to me ⁇ tabolize prebiotics such as FOS, GOS, Lactulose with varying ef ⁇ ficiencies .
  • probiotic strains and specific intestinal bacteria and yeast have been examined upon their in vitro growth in media which comprise 2-O-glyceryl- -D- glucopyranoside or glucose as carbon source. It could be shown that Lactobacillus acidophilus, for instance, shows an increased lag-phase when grown in a medium comprising 2-O-glyceryl- -D- glucopyranoside in contrast to a medium comprising glucose as carbon source. Comparable lag-phases could be observed with Inu- lin and GS as prebioticum (Kneifel, Microbial Ecology in Health and Diseases 12 (2000) : 27-34; Alander et al . , Int Dairy J 11 (2001) : 817-825) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation du 2-o-glycéryl-α-D-glucopyranoside comme prébiotique.
PCT/EP2010/069066 2009-12-11 2010-12-07 Prébiotique WO2011070010A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10787459.6A EP2509450B1 (fr) 2009-12-11 2010-12-07 Prébiotique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09178817.4 2009-12-11
EP09178817A EP2332426A1 (fr) 2009-12-11 2009-12-11 Prébiotique

Publications (1)

Publication Number Publication Date
WO2011070010A1 true WO2011070010A1 (fr) 2011-06-16

Family

ID=42061045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069066 WO2011070010A1 (fr) 2009-12-11 2010-12-07 Prébiotique

Country Status (2)

Country Link
EP (2) EP2332426A1 (fr)
WO (1) WO2011070010A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108641991A (zh) * 2018-07-11 2018-10-12 江苏恒丰强生物技术有限公司 一种复合活菌制剂和其制备方法及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112505A1 (fr) * 2003-06-16 2004-12-29 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales
WO2005092116A1 (fr) * 2004-03-24 2005-10-06 Mars Incorporated Aliment contenant un probiotique et un prebiotique
US20060141097A1 (en) * 2002-10-22 2006-06-29 Mingruo Guo Symbiotic food products comprising oats and methods for manufacturing the same
EP1712139A1 (fr) * 2005-04-15 2006-10-18 Cargill Incorporated Composition à libération d'énergie prolongée
WO2007076534A1 (fr) * 2005-12-29 2007-07-05 Hill's Pet Nutrition, Inc. Methode permettant de modifier la flore intestinale chez des animaux
WO2008034158A2 (fr) 2006-09-21 2008-03-27 Technische Universität Graz Procédé de production de dérivés de glucose
WO2008119012A2 (fr) * 2007-03-27 2008-10-02 The Procter & Gamble Company Procédés et kits destinés à l'administration de probiotiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141097A1 (en) * 2002-10-22 2006-06-29 Mingruo Guo Symbiotic food products comprising oats and methods for manufacturing the same
WO2004112505A1 (fr) * 2003-06-16 2004-12-29 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales
WO2005092116A1 (fr) * 2004-03-24 2005-10-06 Mars Incorporated Aliment contenant un probiotique et un prebiotique
EP1712139A1 (fr) * 2005-04-15 2006-10-18 Cargill Incorporated Composition à libération d'énergie prolongée
WO2007076534A1 (fr) * 2005-12-29 2007-07-05 Hill's Pet Nutrition, Inc. Methode permettant de modifier la flore intestinale chez des animaux
WO2008034158A2 (fr) 2006-09-21 2008-03-27 Technische Universität Graz Procédé de production de dérivés de glucose
WO2008119012A2 (fr) * 2007-03-27 2008-10-02 The Procter & Gamble Company Procédés et kits destinés à l'administration de probiotiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALANDER ET AL., INT DAIRY J, vol. 11, 2001, pages 817 - 825
CABACUNGAN E.; PIERINGER A. R.: "Evidence of tetraglucoside substituent on the liopteichoic acid of Streptococcus faecium ATCC9790", FEMS MICROBIOLOGY LETTERS, vol. 26, 1985, pages 49 - 52, XP002579106 *
KAUSHAL GP ET AL., ARCH. BIOCHEM. BIO- PHYS., vol. 272, 1989, pages 481 - 487
KNEIFEL, MICROBIAL ECOLOGY IN HEALTH AND DISEASES, vol. 12, 2000, pages 27 - 34
MARIN K. ET AL., J. BACTERIOL., vol. 180, 1998, pages 4843 - 4849
NAKANO H. ET AL., J. BIOSCI. BIOENG., vol. 95, 2003, pages 583 - 588
TAKENAKA F. ET AL., BIOSCI. BIOTECHNOL. BIOCHEM., vol. 64, 2000, pages 378 - 385
TAKENAKA F.; UCHIYAMA H., BIOSCI. BIOTECHNOL. BIOCHEM., vol. 64, 2000, pages 1821 - 1826

Also Published As

Publication number Publication date
EP2509450A1 (fr) 2012-10-17
EP2332426A1 (fr) 2011-06-15
EP2509450B1 (fr) 2014-06-11

Similar Documents

Publication Publication Date Title
CN100400645C (zh) 益生菌的联合
US8551543B2 (en) Symbiotic maple product compositions and methods
KR100514592B1 (ko) 공역화 리놀렌산을 생산하는 신규한 균주, 이를 함유하는 캡슐제 및 이를 이용한 기능성 식품
US11026983B2 (en) Bifidobacterium breve CBT BR3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same
WO2007010977A1 (fr) Nouvelle bacterie appartenant au genre bifidobacterium et utilisation de celle-ci
CN1916161A (zh) 一种肠道益生菌包埋保护方法
OA13142A (en) Nutritional formulations containing synbiotic substances.
KR101868517B1 (ko) 다양한 생리활성과 열 안정성이 우수한 프로바이오틱 락토바실러스 퍼멘텀 pl9119
Goderska et al. Comparision of growth of Lactobacillus acidophilus and Bifidobacterium bifidum species in media suplemented with selected saccharides including prebiotics
CN103189499A (zh) 乳酸菌和/或双歧杆菌的存活能力提高剂
EP3065570B1 (fr) Composition
GB2418431A (en) Metabolically active micro organisms and methods for their production
Sip et al. Probiotics and prebiotics
Mumcu et al. Effects of prebiotics on growth and acidifying activity of probiotic bacteria.
KR100868777B1 (ko) Ｒｓ３ 유형의 저항 전분에 대해 분해능이 있는비피도박테리움 아도레스센티스를 유효성분으로 함유하는것을 특징으로 하는 식품 조성물
EP2509450B1 (fr) Prébiotique
CN109688839A (zh) 发酵的婴儿配方物
KR102642547B1 (ko) 레비락토바실러스 브레비스 WiKim0168을 포함하는 숙취 해소 및 간 기능 개선용 조성물
KR102642548B1 (ko) 페디오코커스 에시디락티시 WiKim0170을 포함하는 숙취 해소 및 간 기능 개선용 조성물
Paliy et al. Influence of various prebiotic components on the main growth indicators of probiotic bacteria
KR20230139410A (ko) 발효 및 섭취를 위한 프로바이오틱스 제조방법
Sreeja et al. Bifidus milks

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10787459

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010787459

Country of ref document: EP